NCT06907251

Dapagliflozin for Long COVID Syndrome

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (estimated)
• Sponsor: Ottawa Heart Institute Research Corporation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Detailed description

This is a multi-centre, randomized, placebo-controlled trial (Figure 4). We will randomly assign patients with long COVID to 12 months of dapagliflozin 10 mg or placebo daily. The 10 mg daily dose of dapagliflozin was used in large clinical trials (44,48) and is the Health Canada approved dose for heart and kidney disease. Additionally, this dose was used in the MRI study of body composition (58) and the RCT in patients with acute COVID-19 (54). Eligible patients with long COVID will be recruited from post COVID programs or advertisement through-multi-media. A total of 192 participants will be enrolled and this is anticipated to take 3 years. Participants will be followed for the entire duration of the study. Based on a study duration of 5 years (3-year recruitment, 2-year follow-up), patients will be followed for a median of 3.5 years.

Conditions

• COVID - 19
• Long COVID Syndrome
• SARS CoV-2

Interventions

Type	Name	Description
DRUG	Dapagliflozin (DAPA)	Dapagliflozin 10mg orally once a day for 12 months
DRUG	Placebo	Participants will receive a matching placebo taken once daily by mouth for 12 months.

Timeline

• Start date: 2026-04-01
• Primary completion: 2028-06-30
• Completion: 2029-06-30
• First posted: 2025-04-02
• Last updated: 2026-02-20

Locations

1 site across 1 country: Canada